Today's Analyst Stock Ratings | Upgrades, Downgrades

							Get Alert
May 8, 2026	PRTAProthena Corp	$8.93	123.96%	Jason N. ButlerCitizens 70%	19 20	Previous Market Outperform Current Market Outperform	Get Alert
Feb 20, 2026	PRTAProthena Corp	$8.93	34.38%	Brian AbrahamsRBC Capital 59%	11 12	Previous Sector Perform Current Sector Perform	Get Alert
Dec 1, 2025	PRTAProthena Corp	$8.93	112.77%	Jason ButlerCitizens 78%	11 19	Previous Market Outperform Current Market Outperform	Get Alert
Nov 7, 2025	PRTAProthena Corp	$8.93	235.95%	Andrew S. FeinHC Wainwright & Co. 71%	20 30	Previous Buy Current Buy	Get Alert
Nov 7, 2025	PRTAProthena Corp	$8.93	23.18%	Brian AbrahamsRBC Capital 59%	10 11	Previous Sector Perform Current Sector Perform	Get Alert
Oct 28, 2025	PRTAProthena Corp	$8.93	303.14%	Yasmeen RahimiPiper Sandler 62%	15 36	Previous Overweight Current Overweight	Get Alert
Oct 7, 2025	PRTAProthena Corp	$8.93	123.96%	Andrew S. FeinHC Wainwright & Co. 71%	14 20	Previous Buy Current Buy	Get Alert
Sep 2, 2025	PRTAProthena Corp	$8.93	23.18%	Jason ButlerJMP Securities 78%	11 29	Previous Market Outperform Current Market Outperform	Get Alert
Aug 28, 2025	PRTAProthena Corp	$8.93	67.97%	Yasmeen RahimiPiper Sandler 62%	15 81	Previous Overweight Current Overweight	Get Alert
Aug 28, 2025	PRTAProthena Corp	$8.93	101.57%	Rudy LiChardan Capital 84%	18 18	Previous Buy Current Buy	Get Alert
Aug 5, 2025	PRTAProthena Corp	$8.93	11.98%	Brian AbrahamsRBC Capital 59%	10 18	Previous Sector Perform Current Sector Perform	Get Alert
Aug 5, 2025	PRTAProthena Corp	$8.93	56.77%	Andrew S. FeinHC Wainwright & Co. 71%	14 14	Previous Buy Current Buy	Get Alert
Aug 5, 2025	PRTAProthena Corp	$8.93	101.57%	Rudy LiChardan Capital 84%	18 18	Previous Buy Current Buy	Get Alert
Jun 20, 2025	PRTAProthena Corp	$8.93	—	Eric SchmidtCantor Fitzgerald 50%	—	Previous Neutral Current Neutral	Get Alert
May 28, 2025	PRTAProthena Corp	$8.93	-55.21%	Tazeen AhmadB of A Securities 61%	4 22	Previous Neutral Current Underperform	Get Alert
May 27, 2025	PRTAProthena Corp	$8.93	—	Jay OlsonOppenheimer 68%	—	Previous Outperform Current Perform	Get Alert
May 27, 2025	PRTAProthena Corp	$8.93	807.05%	Yasmeen RahimiPiper Sandler 62%	81 110	Previous Overweight Current Overweight	Get Alert
May 27, 2025	PRTAProthena Corp	$8.93	224.75%	Jason ButlerJMP Securities 78%	29 78	Previous Market Outperform Current Market Outperform	Get Alert
May 27, 2025	PRTAProthena Corp	$8.93	101.57%	Rudy LiChardan Capital 84%	18 40	Previous Buy Current Buy	Get Alert
May 27, 2025	PRTAProthena Corp	$8.93	56.77%	Andrew FeinHC Wainwright & Co. 74%	14 30	Previous Buy Current Buy	Get Alert
May 9, 2025	PRTAProthena Corp	$8.93	235.95%	Andrew FeinHC Wainwright & Co. 74%	30 48	Previous Buy Current Buy	Get Alert
May 9, 2025	PRTAProthena Corp	$8.93	773.46%	Jason ButlerJMP Securities 78%	78 80	Previous Market Outperform Current Market Outperform	Get Alert
May 9, 2025	PRTAProthena Corp	$8.93	347.93%	Rudy LiChardan Capital 84%	40 40	Previous Buy Current Buy	Get Alert
Feb 26, 2025	PRTAProthena Corp	$8.93	1131.8%	Yasmeen RahimiPiper Sandler 62%	94 110	Previous Overweight Current Overweight	Get Alert
Feb 24, 2025	PRTAProthena Corp	$8.93	437.51%	Andrew FeinHC Wainwright & Co. 74%	48 48	Previous Buy Current Buy	Get Alert
Feb 21, 2025	PRTAProthena Corp	$8.93	123.96%	Brian AbrahamsRBC Capital 59%	20 24	Previous Sector Perform Current Sector Perform	Get Alert
Feb 21, 2025	PRTAProthena Corp	$8.93	—	Eric SchmidtCantor Fitzgerald 50%	—	Previous Overweight Current Overweight	Get Alert
Feb 21, 2025	PRTAProthena Corp	$8.93	795.86%	Jason ButlerCitizens Capital Markets 78%	80 80	Previous Market Outperform Current Market Outperform	Get Alert
Feb 21, 2025	PRTAProthena Corp	$8.93	437.51%	Andrew FeinHC Wainwright & Co. 74%	48 48	Previous Buy Current Buy	Get Alert
Feb 21, 2025	PRTAProthena Corp	$8.93	347.93%	Rudy LiChardan Capital 84%	40 40	Previous Buy Current Buy	Get Alert
Feb 7, 2025	PRTAProthena Corp	$8.93	594.29%	Jay OlsonOppenheimer 68%	58 62	Previous Outperform Current Outperform	Get Alert
Dec 20, 2024	PRTAProthena Corp	$8.93	437.51%	Andrew FeinHC Wainwright & Co. 74%	48 84	Previous Buy Current Buy	Get Alert
Dec 20, 2024	PRTAProthena Corp	$8.93	347.93%	Rudy LiChardan Capital 84%	40	Previous Initiates Current Buy	Get Alert
Dec 19, 2024	PRTAProthena Corp	$8.93	549.5%	Jay OlsonOppenheimer 68%	58 62	Previous Outperform Current Outperform	Get Alert
Dec 19, 2024	PRTAProthena Corp	$8.93	146.36%	Tazeen AhmadB of A Securities 61%	22 26	Previous Neutral Current Neutral	Get Alert
Nov 13, 2024	PRTAProthena Corp	$8.93	840.65%	Andrew FeinHC Wainwright & Co. 74%	84 84	Previous Buy Current Buy	Get Alert
Oct 1, 2024	PRTAProthena Corp	$8.93	247.14%	Tazeen AhmadB of A Securities 61%	31 33	Previous Neutral Current Neutral	Get Alert
Oct 1, 2024	PRTAProthena Corp	$8.93	840.65%	Andrew FeinHC Wainwright & Co. 74%	84 84	Previous Buy Current Buy	Get Alert
Sep 30, 2024	PRTAProthena Corp	$8.93	—	Charles DuncanCantor Fitzgerald 68%	—	Previous Current Overweight	Get Alert
Aug 14, 2024	PRTAProthena Corp	$8.93	594.29%	Jay OlsonOppenheimer 68%	62 66	Previous Outperform Current Outperform	Get Alert
Aug 12, 2024	PRTAProthena Corp	$8.93	—	Charles DuncanCantor Fitzgerald 68%	—	Previous Current Overweight	Get Alert
Aug 9, 2024	PRTAProthena Corp	$8.93	168.76%	Brian AbrahamsRBC Capital 59%	24 28	Previous Sector Perform Current Sector Perform	Get Alert
Jun 26, 2024	PRTAProthena Corp	$8.93	213.55%	Brian AbrahamsRBC Capital 59%	28 28	Previous Sector Perform Current Sector Perform	Get Alert
May 9, 2024	PRTAProthena Corp	$8.93	829.45%	Jason ButlerJMP Securities 78%	83 85	Previous Market Outperform Current Market Outperform	Get Alert
May 9, 2024	PRTAProthena Corp	$8.93	840.65%	Andrew FeinHC Wainwright & Co. 74%	84 90	Previous Buy Current Buy	Get Alert
Apr 10, 2024	PRTAProthena Corp	$8.93	—	Charles DuncanCantor Fitzgerald 68%	—	Previous Current Overweight	Get Alert
Mar 13, 2024	PRTAProthena Corp	$8.93	907.84%	Andrew FeinHC Wainwright & Co. 74%	90 90	Previous Buy Current Buy	Get Alert
Feb 20, 2024	PRTAProthena Corp	$8.93	795.86%	Jay OlsonOppenheimer 68%	80 98	Previous Outperform Current Outperform	Get Alert
Feb 16, 2024	PRTAProthena Corp	$8.93	851.85%	Jason ButlerJMP Securities 78%	81 85	Previous Market Outperform Current Market Outperform	Get Alert
Feb 16, 2024	PRTAProthena Corp	$8.93	291.94%	Brian AbrahamsRBC Capital 59%	35 36	Previous Sector Perform Current Sector Perform	Get Alert
Jan 30, 2024	PRTAProthena Corp	$8.93	325.53%	Tazeen AhmadB of A Securities 61%	38 68	Previous Buy Current Neutral	Get Alert
Jan 25, 2024	PRTAProthena Corp	$8.93	303.14%	Brian AbrahamsRBC Capital 59%	36 43	Previous Sector Perform Current Sector Perform	Get Alert
Jan 9, 2024	PRTAProthena Corp	$8.93	874.24%	Charles DuncanCantor Fitzgerald 68%	87 129	Previous Overweight Current Overweight	Get Alert
Dec 18, 2023	PRTAProthena Corp	$8.93	1344.57%	Charles DuncanCantor Fitzgerald 68%	129 129	Previous Overweight Current Overweight	Get Alert
Dec 12, 2023	PRTAProthena Corp	$8.93	594.29%	Neena Bitritto-GargDeutsche Bank 56%	62	Previous Initiates Current Buy	Get Alert
Nov 3, 2023	PRTAProthena Corp	$8.93	807.05%	Jason ButlerJMP Securities 78%	81 83	Previous Market Outperform Current Market Outperform	Get Alert
Oct 23, 2023	PRTAProthena Corp	$8.93	1344.57%	Charles DuncanCantor Fitzgerald 68%	129	Previous Overweight Current Overweight	Get Alert
Aug 22, 2023	PRTAProthena Corp	$8.93	1344.57%	Charles DuncanCantor Fitzgerald 68%	129	Previous Overweight Current Overweight	Get Alert
Aug 4, 2023	PRTAProthena Corp	$8.93	907.84%	Andrew FeinHC Wainwright & Co. 74%	90	Previous Buy Current Buy	Get Alert
Aug 4, 2023	PRTAProthena Corp	$8.93	829.45%	Jason ButlerJMP Securities 78%	82 83	Previous Outperform Current Outperform	Get Alert
Jul 18, 2023	PRTAProthena Corp	$8.93	1344.57%	Charles DuncanCantor Fitzgerald 68%	129	Previous Overweight Current Overweight	Get Alert
Jul 18, 2023	PRTAProthena Corp	$8.93	907.84%	Andrew FeinHC Wainwright & Co. 74%	90	Previous Buy Current Buy	Get Alert
Jul 11, 2023	PRTAProthena Corp	$8.93	1344.57%	Charles DuncanCantor Fitzgerald 68%	129	Previous Overweight Current Overweight	Get Alert
Jul 11, 2023	PRTAProthena Corp	$8.93	818.25%	Jason ButlerJMP Securities 78%	82	Previous Market Outperform Current Market Outperform	Get Alert
Jun 28, 2023	PRTAProthena Corp	$8.93	1344.57%	Charles DuncanCantor Fitzgerald 68%	129	Previous Overweight Current Overweight	Get Alert
Jun 21, 2023	PRTAProthena Corp	$8.93	1344.57%	Charles DuncanCantor Fitzgerald 68%	129	Previous Overweight Current Overweight	Get Alert
May 8, 2023	PRTAProthena Corp	$8.93	1243.78%	Charles DuncanCantor Fitzgerald 68%	98 120	Previous Current Overweight	Get Alert
May 5, 2023	PRTAProthena Corp	$8.93	571.89%	Brian AbrahamsRBC Capital 59%	55 60	Previous Current Sector Perform	Get Alert
May 5, 2023	PRTAProthena Corp	$8.93	818.25%	Jason ButlerJMP Securities 78%	82	Previous Current Market Outperform	Get Alert
May 5, 2023	PRTAProthena Corp	$8.93	907.84%	Andrew FeinHC Wainwright & Co. 74%	75 90	Previous Current Buy	Get Alert
Apr 25, 2023	PRTAProthena Corp	$8.93	515.9%	Brian AbrahamsRBC Capital 59%	55	Previous Current Sector Perform	Get Alert
Apr 24, 2023	PRTAProthena Corp	$8.93	795.86%	Rudy LiSVB Leerink 84%	80	Previous Initiates Current Outperform	Get Alert
Apr 3, 2023	PRTAProthena Corp	$8.93	739.87%	Andrew FeinHC Wainwright & Co. 74%	75	Previous Current Buy	Get Alert
Feb 27, 2023	PRTAProthena Corp	$8.93	706.27%	Neena Bitritto-GargCitigroup 56%	72 76	Previous Current Buy	Get Alert
Feb 24, 2023	PRTAProthena Corp	$8.93	739.87%	Andrew FeinHC Wainwright & Co. 74%	75	Previous Current Buy	Get Alert
Jan 27, 2023	PRTAProthena Corp	$8.93	952.63%	Yasmeen RahimiPiper Sandler 62%	94	Previous Initiates Current Overweight	Get Alert
Dec 21, 2022	PRTAProthena Corp	$8.93	997.42%	Charles DuncanCantor Fitzgerald 68%	91 98	Previous Current Overweight	Get Alert
Nov 4, 2022	PRTAProthena Corp	$8.93	515.9%	Brian AbrahamsRBC Capital 59%	52 55	Previous Outperform Current Sector Perform	Get Alert
Oct 24, 2022	PRTAProthena Corp	$8.93	695.07%	Neena Bitritto-GargCitigroup 56%	65 71	Previous Current Buy	Get Alert
Sep 29, 2022	PRTAProthena Corp	$8.93	1131.8%	Jay OlsonOppenheimer 68%	100 110	Previous Current Outperform	Get Alert
Sep 28, 2022	PRTAProthena Corp	$8.93	—	Tazeen AhmadB of A Securities 61%	—	Previous Neutral Current Buy	Get Alert
Sep 28, 2022	PRTAProthena Corp	$8.93	482.31%	Brian AbrahamsRBC Capital 59%	45 52	Previous Current Outperform	Get Alert
May 25, 2022	PRTAProthena Corp	$8.93	459.91%	Jason ButlerJMP Securities 78%	50 77	Previous Current Market Outperform	Get Alert
May 2, 2022	PRTAProthena Corp	$8.93	403.92%	Brian AbrahamsRBC Capital 59%	45 82	Previous Current Outperform	Get Alert
Nov 19, 2021	PRTAProthena Corp	$8.93	762.26%	Gobind SinghJMP Securities 19%	77	Previous Initiates Current Market Outperform	Get Alert
Sep 30, 2021	PRTAProthena Corp	$8.93	818.25%	Kennen MacKayRBC Capital 53%	59 82	Previous Current Outperform	Get Alert
Sep 27, 2021	PRTAProthena Corp	$8.93	1019.82%	Jay OlsonOppenheimer 68%	90 100	Previous Current Outperform	Get Alert
Sep 20, 2021	PRTAProthena Corp	$8.93	56.77%	Steven FoxFox Advisors 26%	14	Previous Initiates Current Overweight	Get Alert
Sep 17, 2021	PRTAProthena Corp	$8.93	1053.42%	Charles DuncanCantor Fitzgerald 68%	70 103	Previous Current Overweight	Get Alert
Sep 14, 2021	PRTAProthena Corp	$8.93	907.84%	Jay OlsonOppenheimer 68%	82 90	Previous Current Outperform	Get Alert
Aug 9, 2021	PRTAProthena Corp	$8.93	818.25%	Jay OlsonOppenheimer 68%	76 82	Previous Current Outperform	Get Alert
Jul 19, 2021	PRTAProthena Corp	$8.93	560.69%	Kennen MacKayRBC Capital 53%	50 59	Previous Current Outperform	Get Alert
Jul 13, 2021	PRTAProthena Corp	$8.93	706.27%	Neena Bitritto-GargCitigroup 56%	57 72	Previous Current Buy	Get Alert
Jul 13, 2021	PRTAProthena Corp	$8.93	751.06%	Jay OlsonOppenheimer 68%	54 76	Previous Current Outperform	Get Alert
Jul 13, 2021	PRTAProthena Corp	$8.93	739.87%	Andrew FeinHC Wainwright & Co. 74%	58 75	Previous Current Buy	Get Alert
Jun 18, 2021	PRTAProthena Corp	$8.93	448.71%	Tazeen AhmadB of A Securities 61%	49	Previous Underperform Current Neutral	Get Alert
Jun 11, 2021	PRTAProthena Corp	$8.93	459.91%	Kennen MacKayRBC Capital 53%	28 50	Previous Current Outperform	Get Alert
Jun 10, 2021	PRTAProthena Corp	$8.93	549.5%	Andrew FeinHC Wainwright & Co. 74%	33 58	Previous Current Buy	Get Alert
May 26, 2021	PRTAProthena Corp	$8.93	336.73%	Neena Bitritto-GargCitigroup 56%	39	Previous Initiates Current Buy	Get Alert
Feb 12, 2021	PRTAProthena Corp	$8.93	235.95%	Michael YeeJefferies 69%	15 30	Previous Hold Current Buy	Get Alert

Recent Analyst Stock Rating News

Marvell Stock Is Up 180% This Year: BofA Says the Real AI Opportunity Is 5 Times Bigger

Marvell has nearly tripled in 2026, but BofA's Vivek Arya sees its custom AI market reaching $300 billion by 2030. Buy rating, $365 price target.

Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In

FDA extends Exelixis NDA review for zanzalintinib to March 2027. Analyst evaluates stock volatility and revenue outlook.

Lovesac Analysts Cut Their Forecasts After Q2 Earnings

Lovesac beat Q2 EPS estimates but missed sales; raised FY27 EPS guidance, cut revenue outlook, and analysts lowered price targets.

These Analysts Revise Their Forecasts On RH Following Q2 Results

RH beats Q2 earnings estimates but misses revenue; narrows FY2026 outlook. Analysts mostly cut price targets as shares rise 1.5%.

PRO

Morgan Stanley Maintains Overweight on RH, Lowers Price Target to $210

Morgan Stanley analyst Simeon Gutman maintains RH (NYSE:RH) with a Overweight and lowers the price target from $240 to $210.

PRO

Morgan Stanley Maintains Equal-Weight on SolarEdge Technologies, Lowers Price Target to $33

Morgan Stanley analyst David Arcaro maintains SolarEdge Technologies (NASDAQ:SEDG) with a Equal-Weight and lowers the price target from $35 to $33.

PRO

Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $183

Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $182 to $183.

PRO

Morgan Stanley Maintains Equal-Weight on Hertz Global Holdings, Lowers Price Target to $3

Morgan Stanley analyst Adam Jonas maintains Hertz Global Holdings (NASDAQ:HTZ) with a Equal-Weight and lowers the price target from $3.5 to $3.

PRO

Morgan Stanley Maintains Equal-Weight on Avis Budget Gr, Lowers Price Target to $95

Morgan Stanley analyst Andrew Percoco maintains Avis Budget Gr (NASDAQ:CAR) with a Equal-Weight and lowers the price target from $99 to $95.

PRO

Morgan Stanley Maintains Overweight on Aurora Innovation, Raises Price Target to $18

Morgan Stanley analyst Ravi Shanker maintains Aurora Innovation (NASDAQ:AUR) with a Overweight and raises the price target from $14 to $18.

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

What Are Analyst Stock Ratings?

Analyst ratings measure the expected performance of a stock during a given time period. Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders.

Analysts arrive at stock ratings after they research companies’ public financial statements, communicate with executives and customers and interact with companies in other ways.

Most analysts issue ratings 4 times a year, usually at 3-month intervals.

How to Use Analyst Ratings

As an investor or trader, you want to be able to use analyst ratings effectively. Here are steps you can take to understand how to synthesize all the information analysts report about a particular company and how to apply it to your own trades.

Step 1: Check Ratings History

In the short term, look to see whether analysts suggest an initiation, upgrade or downgrade for a particular stock. Understand how the rating changed compared to the previous rating and whether a price target gets announced or changed.

Sometimes the rating stays the same and only the price target changes, which could cause the stock to move in either direction, depending on the significance of the change between the 2 price targets.

Step 2: Check for Other News

In the short term, check to see how the stock reacts to positive or negative news. This will be an indication of the company’s outlook because analyst ratings usually come out after the company announces news (it’ll typically be earnings news).

Step 3: Look at the Sector for News

Check to see if other stocks in the sector also received similar ratings. This could indicate micro news, which refers to when the whole sector or specific company trades in a specific way due to news outside of one company.

Step 4: Look at the Note

If available, look over the analyst note itself. The beginning of the note has the main information of the rating and price target. Investors should also take a look at the summary of the note, which you can find in the first couple pages and give you a concrete overview of the company. This can help you get an understanding of how analysts arrived at their thesis on the stock.

An example of an analyst note. Source: Needham

Step 5: Make a Decision

After reviewing the analyst ratings (and whether the analyst proposes a change or initiation) and find the reason for that note. Make a decision based on the analyst thesis on the company. This should give you guidance on how to make your thesis. Analyst ratings are a good indication of what professionals believe the company or sector will do, helping you get a better understanding of the companies you’re interested in.

Analyst Rating Accuracy

Analyst ratings are not set in stone and nobody knows indefinitely what a stock will do. Therefore, analyst ratings should be taken as an educated guess made by professionals who carefully study the specific company and sector in question. It's not a surprise that the accuracy of each rating can vary by each individual analyst and specific ratings on companies.

In other words, there’s no hard number or percentage on how accurate analyst ratings are because they are like educated guesses on what they think the stock will do based on their research, within that particular sector. In addition, each firm has so many analysts and so many different companies to review that you can compare ratings to glean what you believe is the truth.

Where Analyst Ratings Come From

Analyst ratings come from stock analysts. Analysts “go deep” on companies within a particular industry or sector. Some analysts employ a top-down approach (they start with an industry or sector and look for excellent companies within that industry or sector) and other stock analysts choose a bottom-up approach, which means they start with the company first and connect the dots within that company’s sector or industry. Analysts evaluate:

Financial statements
Economic fundamentals
Suppliers, customers and competitors
Management quality
Business model
Revenue
Expenses
Assets
Liabilities

While these evaluations are done using facts and figures that any investor can access, they come down to a conclusion the analyst must draw. While this isn’t an unqualified opinion, analysts will disagree because their interpretations of the data could vary.

Types of Stock Ratings

Stock ratings can range from simple “buy” and “sell” ratings to “equal weight” and “outperform” ratings. Here’s a quick overview of how analysts rate stocks.

Buy Rating

A “buy” rating indicates that an analyst is optimistic about a stock’s short-term or mid-term growth and recommends that traders purchase the stock. An analyst may even go so far as to indicate that a stock is a “strong buy.” At the same time, you may choose to swing trade the asset for a profit and come back later to start the process all over again.

Sell Rating

A “sell” rating means that an analyst believes the stock will trend downward in a particular time frame. Analysts might even refer to a security as a “strong sell.” Remember, though, you may want to swing trade and come back to this asset in the future even though you just chose to sell, just as you would under a “buy” rating.

Hold

A “hold” rating suggests that investors should not buy more of or sell the specified stock because they believe the stock should perform in a way that’s consistent with the market or will perform similarly to comparable companies within that particular sector. This is akin to the value investing approach that Warren Buffett uses, looking to gain long-term value from a single stock rather than flipping it because of a bad week. As many have said, it’s not a loss until you sell.

Underperform

An “underperform” rating means an analyst indicates that a stock is expected to perform below the market or sector average. And yes, while the underperform rating may not bode well for an asset in the next few weeks, it may not stay that way. Continue to carefully monitor your portfolio to ensure that an underperforming asset hasn’t turned itself around. As companies are faced with the Herculean task of pleasing shareholders, they will push to fix their underperforming stocks, meaning that a stock you wrote off could rise again.

Outperform

An “outperform” rating means that an analyst expects a stock to outperform the market or sector average. While the stock may look to outperform the market or a sector’s average, that doesn’t mean it will continue to soar forever. You must look at an outperform rating as what that asset will do in recent times, but it may not maintain that trajectory.

Equal-Weight

An equal weight rating means that an analyst believes that an individual stock's performance will tie to the average of all the stocks that an analyst covers in that particular sector. This type of rating helps investors get a true comparison of stocks to each other within a particular sector or industry. At the same time, equal-weight ratings could change at any time.

Price Target

A price target is an analyst’s projection of a stock’s future price. A price target is generally set up in a general trade or area where the asset might land. This means that the analyst could get close without hitting the figure on the head. Even so, the analyst wants to get close and better predict the movement of the marketplace and the asset.

Understanding Stock Ratings

Stock ratings are assessments of the investment potential of a particular stock. They are typically created by financial analysts who evaluate a company's financial performance, competitive positioning, and market outlook to provide guidance on the stock's expected future performance.

Ratings typically range from "buy" to "sell," with variations in between, such as "hold," "accumulate," or "neutral." A "buy" rating suggests that the stock is likely to perform well in the future, and investors should consider purchasing it. Conversely, a "sell" rating indicates that the stock is expected to underperform, and investors should consider selling it.

It's important to note that ratings are not guarantees of performance and should not be relied upon solely when making investment decisions. Ratings are just one factor to consider when evaluating a stock's potential, and investors should also conduct their own research and analysis to make informed decisions.

Another thing to keep in mind is that different analysts may have different opinions on a stock, so it's a good idea to consider multiple ratings before making an investment decision.

In addition to analyst ratings, investors can also consider other factors when evaluating a stock, such as its financial statements, management team, industry trends, and overall market conditions. By combining all of these factors, investors can make informed decisions about which stocks to buy or sell.

In summary, stock ratings are an important tool for investors to consider when evaluating a stock's potential, but they should not be the only factor used in investment decision-making. It's important to conduct your own research, consider multiple ratings, and take into account other factors before making an investment decision.

Should You Use Analyst Ratings to Inform Your Own Trades?

You can definitely use analyst ratings to inform your own trades and inform your own thesis but it’s a good idea to do your own research. However, analyst ratings are just one step in what should be a much larger investment strategy. Don’t fall in love with just one analyst. Compare notes. Look into how these ratings match with activity on the market and current events. Plus, remember that an analyst rating could easily be incorrect. No one is perfect, but these ratings are a good place to start.

Visit Benzinga News for more guidance on how to research companies and make decisions about research, trading and investing.

Compare Online Stock Brokers

Claim Exclusive Offers

Interactive Brokers Review
Good Fit For:
Active and Global Traders
VIEW PROS & CONS:
Securely through Interactive Brokers’ website
Plus500 Review
Good Fit For:
Leveraged Trading
VIEW PROS & CONS:
securely through Plus500 Yield's website
public.com Review
Good Fit For:
Trading Ideas
VIEW PROS & CONS:
securely through public.com's website
Robinhood Review
Good Fit For:
Commission-Free Mobile Trading
VIEW PROS & CONS:
securely through Robinhood's website
TradeZero Review
Good Fit For:
Active Short Sellers
VIEW PROS & CONS:
securely through TradeZero [SPONSORED]'s website